Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Knisely JPS Yu JB Flanigan J Sznol

    2020-08-12


    2. Knisely JPS, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VLS. Radiosurgery for mela-noma GW-311616 metastases in the ipilimumab era and the possibility GW-311616 of longer survival. J Neurosurg. 2012; 117:227-233.
    3. Nieder C, Marienhagen K, Dalhaug A, Aandahl G, Haukland E, Pawinski A. Impact of systemic treatment on survival after whole brain radio-therapy in patients with brain metastases. Med Oncol. 2014;31:927.
    4. Niwinska A. Brain metastases as site of first and isolated recurrence of breast cancer: the role of 
    5. Bourke RS, West CR, Chheda G, Tower DB. Ki-netics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intrave-nous injection in a primate. Cancer Res. 1973;33: 1735-1746.
    6. Miyajima M, Kusuhara H, Takahashi K, et al. Investigation of the effect of active efflux at the blood-brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system. J Pharm Sci. 2013;102:3309-3319.
    8. Morikawa A, Peereboom DM, Smith QR, et al. Clinical evidence for drug penetration of
    capecitabine and lapatinib uptake in resected brain metastases from women with metastatic breast cancer. J Clin Oncol. 2013;15(suppl):514.
    9. Jacobs SS, Fox E, Dennie C, Morgan LB, McCully CL, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin Cancer Res. 2005;11:1669-1674.
    11. Yule SM, Price L, Pearson ADJ, Boddy AV. Cyclo-phosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin Cancer Res. 1997;3:1985-1992.
    WORLD NEUROSURGERY -: e1-e10, - 2019 www.journals.elsevier.com/world-neurosurgery e9
    ORIGINAL ARTICLE
    TIMOUR AL-KHINDI ET AL. EFFECT OF POST-SRS SYSTEMIC THERAPY ON PATIENT OUTCOMES
    14. von Holst H, Knochenhauer E, Blomgren H, et al. Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas. Acta Neurochir (Wien). 1990;104:13-16.
    15. Chang AY, Ying XX. Brain metastases from breast cancer and response to treatment with eribulin: a case series. Breast Cancer (Auckl). 2015;9:19-24.
    16. Deng Y, Feng W, Wu J, et al. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol Clin Oncol. 2014;2:116-120.
    18. Vergote I, Abram P. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Ann Oncol. 2006;17:200-204.
    21. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009; 11:80-91.
    22. Chalmers AJ, Jackson A, Swaisland H, et al. Re-sults of stage 1 of the oparatic trial: a phase I study of olaparib in combination with temozolomide in patients with relapsed glioblastoma. J Clin Oncol. 2014;32. abstract 2025.
    23. Koba T, Kijima T, Takimoto T, et al. Rapid intracranial response to osimertinib, without 
    radiotherapy, in nonsmall cell lung cancer pa-tients harboring the EGFR T790M mutation: two case reports. Medicine (Baltimore). 2017;96, e6087.
    25. Hingorani M, Dixit S, Maraveyas A. Pazopanib-induced regression of brain metastasis after whole brain palliative radiotherapy in metastatic renal cell cancer progressing on first-line sunitinib: a case report. World J Oncol. 2014;5:223-227.
    26. Jacus MO, Daryani VM, Harstead KE, et al. Phar-macokinetic properties of anticancer agents for the treatment of CNS tumors: update of the literature. Clin Pharmacokinet. 2016;55:297-311.
    27. Kimelberg HK. Tamoxifen as a powerful neuro-protectant in experimental stroke and implica-tions for human stroke therapy. Recent Pat CNS Drug Discov. 2008;3:104-108.
    28. Cohen JV, Kluger HM. Systemic immunotherapy for the treatment of brain metastases. Front Oncol. 2016;6:49.
    30. Vaidhyanathan S, Mittapalli RK, Sarkaria JN, Elmquist WF. Factors influencing the CNS distri-bution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metab Dispos. 2014;42:1292-1300.
    31. Boyle FM, Eller SL, Grossman SA. Penetration of intra-arterially administered vincristine in experi-mental brain tumor. Neuro Oncol. 2004;6:300-305.
    32. Faller BA, Pandit TN. Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer. Clin Med Insights Oncol. 2011;5:131-144.
    33. Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32: 2100-2108.